Search Within

Andrew D Zelenetz

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (61)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (127)
  2. Center for Hematologic Malignancies (127)
  3. Department of Medicine (127)
  4. Epidemiology and Biostatistics (127)
  5. Hematologic Malignancies, Division of (127)
  6. Lymphoma (127)

More Groups

People
  1. Craig Moskowitz (66)
  2. Paul Hamlin (56)
  3. Anas Younes (51)
  4. Ariela Noy (49)
  5. David Straus (48)
  6. Anita Kumar (47)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (9)
  4. 2022 (5)
  5. 2021 (11)
  6. 2020 (8)

More Years

Publications
  1. Blood (52)
  2. Journal of Clinical Oncology (13)
  3. Hematological Oncology (10)
  4. British Journal of Haematology (8)
  5. Blood Advances (5)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (57)
  2. American Society of Clinical Oncology (13)
  3. Wiley Blackwell (10)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons (8)
  6. Elsevier Inc. (7)

More Publishers

Results (127)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The utility of consolidative upfront high dose chemoradiotherapy and ASCT in patients with mantle cell lymphoma (MCL)
    Meeting Abstract

    Persky, Daniel; Portlock, Carol S.; Lessac-Chenen, Simone; Iasonos, Alexia; Zelenetz, Andrew D; Kewalramani, Tarun; Rice, David; Yahalom, Joachim; Nimer, Stephen D; Moskowitz, Craig H.
    Blood (2005)

    Fulltext@MSK | Save
  • The follicular lymphoma international prognostic index (FLIPI) is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma
    Meeting Abstract

    Halaas, J. L.; Teruya-Feldstein, J.; Filippa, D. A.; Moskowitz, C.; Naresh, K. N.; Zelenetz, A. D.
    Blood (2004)

    Fulltext@MSK | Save
  • Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients - Reply
    Journal Article

    Sgouros, G.; Squeri, S.; Ballangrud, A. M.; Kolbert, K.; Teitcher, J. B.; Panageas, K. S.; Finn, R. D.; Divgi, C. R.; Larson, S. M.; Zelenetz, A. D.
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save
  • Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: Assessment of tumor dose-response
    Journal Article

    Sgouros, G.; Squeri, S.; Ballangrud, A. M.; Kolbert, K. S.; Teitcher, J. B.; Panageas, K. S.; Finn, R. D.; Divgi, C. R.; Larson, S. M.; Zelenetz, A. D.
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save
  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Hamlin, P. A.; Zelenetz, A. D.; Kewalramani, T.; Qin, J.; Satagopan, J. M.; Verbel, D.; Noy, A.; Portlock, C. S.; Straus, D. J.; Yahalom, J.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Factors predicting outcome in patients with primary refractory intermediate grade lymphoma (IGL) eligible for high dose chemoradiotherapy (HDT) and autologous stem cell transplant (ASCT)
    Meeting Abstract

    Kewalramani, T.; Hedrick, E. E.; Donnelly, G. B.; Satagopan, J. M.; Hunte, S.; Priovolos, A.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (1999)

    Fulltext@MSK | Save
  • Persistent gallium avidity after second-line chemotherapy in Hodgkin's disease (HD) and intermediate-grade non-hodgkin's lymphoma (IGL) does not predict outcome following autologous stem cell transplantation (ASCT)
    Meeting Abstract

    Donnelly, G. B.; Hedrick, E. E.; Kewalramani, T.; Satagopan, J. M.; Walits, J.; Yahalom, J.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (1999)

    Fulltext@MSK | Save